Daiichi Sankyo (United States)

Homepage: dsi.com

Parent institution: Daiichi-Sankyo (Japan)

ROR: 055werx92

OpenAlex ID: I4210162815

Edoxaban versus Warfarin in Patients with Atrial Fibrillation

2013 · Robert P. Giugliano, Christian T. Ruff, et al. · New England Journal of Medicine · 5,159

PDF

Trastuzumab Deruxtecan in Previously Treated HER2-Low Advanced Breast Cancer

2022 · Shanu Modi, William Jacot, et al. · New England Journal of Medicine · 2,664

PDF

Cytochrome P-450 Polymorphisms and Response to Clopidogrel

2008 · Jessica L. Mega, Sandra L. Close, et al. · New England Journal of Medicine · 2,498

PDF

Trastuzumab Deruxtecan in Previously Treated HER2-Positive Breast Cancer

2019 · Shanu Modi, Cristina Saura, et al. · New England Journal of Medicine · 2,000

PDF

Edoxaban for the Treatment of Cancer-Associated Venous Thromboembolism

2017 · Gary E. Raskob, Nick van Es, et al. · New England Journal of Medicine · 1,633

Trastuzumab Deruxtecan in Previously Treated HER2-Positive Gastric Cancer

2020 · Kohei Shitara, Yung-Jue Bang, et al. · New England Journal of Medicine · 1,326

PDF

Trastuzumab Deruxtecan in HER2 -Mutant Non–Small-Cell Lung Cancer

2021 · Bob T. Li, Egbert F. Smit, et al. · New England Journal of Medicine · 1,022

PDF

Antitumor Activity and Safety of Trastuzumab Deruxtecan in Patients With HER2-Low–Expressing Advanced Breast Cancer: Results From a Phase Ib Study

2020 · Shanu Modi, Haeseong Park, et al. · Journal of Clinical Oncology · 787

Common polymorphisms of CYP2C19 and CYP2C9 affect the pharmacokinetic and pharmacodynamic response to clopidogrel but not prasugrel

2007 · J.T. BRANDT, S.L. CLOSE, et al. · Journal of Thrombosis and Haemostasis · 734

Trastuzumab deruxtecan versus trastuzumab emtansine in patients with HER2-positive metastatic breast cancer: updated results from DESTINY-Breast03, a randomised, open-label, phase 3 trial

2022 · Sara A Hurvitz, Roberto Hegg, et al. · The Lancet · 687

PDF

Cytochrome P450 Genetic Polymorphisms and the Response to Prasugrel

2009 · Jessica L. Mega, Sandra L. Close, et al. · Circulation · 651

Genetic variants in ABCB1 and CYP2C19 and cardiovascular outcomes after treatment with clopidogrel and prasugrel in the TRITON–TIMI 38 trial: a pharmacogenetic analysis

2010 · Jessica L Mega, Sandra L Close, et al. · The Lancet · 615

Tivantinib for second-line treatment of advanced hepatocellular carcinoma: a randomised, placebo-controlled phase 2 study

2012 · Armando Santoro, Lorenza Rimassa, et al. · The Lancet Oncology · 554

Safety, pharmacokinetics, and antitumour activity of trastuzumab deruxtecan (DS-8201), a HER2-targeting antibody–drug conjugate, in patients with advanced breast and gastric or gastro-oesophageal tumours: a phase 1 dose-escalation study

2017 · Toshihiko Doi, Kohei Shitara, et al. · The Lancet Oncology · 505

Quizartinib versus salvage chemotherapy in relapsed or refractory FLT3-ITD acute myeloid leukaemia (QuANTUM-R): a multicentre, randomised, controlled, open-label, phase 3 trial

2019 · Jorge E Cortes, Samer Khaled, et al. · The Lancet Oncology · 485

Pexidartinib versus placebo for advanced tenosynovial giant cell tumour (ENLIVEN): a randomised phase 3 trial

2019 · William D Tap, Hans Gelderblom, et al. · The Lancet · 482

PDF

Evaluation of the novel factor Xa inhibitor edoxaban compared with warfarin in patients with atrial fibrillation: Design and rationale for the Effective aNticoaGulation with factor xA next GEneration in Atrial Fibrillation–Thrombolysis In Myocardial Infarction study 48 (ENGAGE AF–TIMI 48)

2010 · Christian T. Ruff, Robert P. Giugliano, et al. · American Heart Journal · 480

Clinical Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of the Novel Factor Xa Inhibitor Edoxaban in Healthy Volunteers

2010 · Koichiro Ogata, Jeanne Mendell‐Harary, et al. · The Journal of Clinical Pharmacology · 453

Trastuzumab deruxtecan (DS-8201) in patients with HER2-expressing metastatic colorectal cancer (DESTINY-CRC01): a multicentre, open-label, phase 2 trial

2021 · Salvatore Siena, Maria Di Bartolomeo, et al. · The Lancet Oncology · 422

Quizartinib plus chemotherapy in newly diagnosed patients with FLT3-internal-tandem-duplication-positive acute myeloid leukaemia (QuANTUM-First): a randomised, double-blind, placebo-controlled, phase 3 trial

2023 · Harry P Erba, Pau Montesinos, et al. · The Lancet · 418

Association between edoxaban dose, concentration, anti-Factor Xa activity, and outcomes: an analysis of data from the randomised, double-blind ENGAGE AF-TIMI 48 trial

2015 · Christian T Ruff, Robert P Giugliano, et al. · The Lancet · 405

Youth-Onset Type 2 Diabetes Consensus Report: Current Status, Challenges, and Priorities

2016 · Kristen J. Nadeau, Barbara J. Anderson, et al. · Diabetes Care · 381

PDF

Trastuzumab deruxtecan versus treatment of physician's choice in patients with HER2-positive metastatic breast cancer (DESTINY-Breast02): a randomised, open-label, multicentre, phase 3 trial

2023 · Fabrice André, Yeon Hee Park, et al. · The Lancet · 379

The P-Glycoprotein Transport System and Cardiovascular Drugs

2013 · Jeffrey D. Wessler, Laura T. Grip, et al. · Journal of the American College of Cardiology · 362

Targeting HER2 with Trastuzumab Deruxtecan: A Dose-Expansion, Phase I Study in Multiple Advanced Solid Tumors

2020 · Junji Tsurutani, Hiroji Iwata, et al. · Cancer Discovery · 354

Works count: 1,854

Citation count: 212,900